NJ Bio
NJ Bio is a leading contract research organization specializing in bioconjugation, antibody-drug conjugates (ADCs), and advanced analytical services. The company is committed to scientific excellence, innovation, and providing high-quality, customizable solutions to accelerate drug discovery and development in the biopharmaceutical industry. With a focus on next-generation ADCs, bioanalytical services, and cutting-edge technology, NJ Bio aims to be the largest CRO in the USA for ADC and bioconjugation research.
Industries
Nr. of Employees
medium (51-250)
Products
ADC characterization platform (structural NMR integration)
Analytical platform that integrates high-resolution NMR-derived structural and footprinting data with other analytics to produce higher-order structural insights for conjugate design and differentiation.
ADC characterization platform (structural NMR integration)
Analytical platform that integrates high-resolution NMR-derived structural and footprinting data with other analytics to produce higher-order structural insights for conjugate design and differentiation.
Services
End-to-end conjugation workflows including selection and execution of conjugation methods, purification and analytical characterization for ADCs, AOCs and other protein conjugates.
Design, custom synthesis and scale-up of payloads and linkers, including integrated payload-linker production for conjugation studies and early CMC supply.
Process optimization and scale-up services to transition synthetic routes and conjugate processes from discovery to pilot and manufacturing scales with CMC support.
Access to high-field NMR instruments and BioNMR experiments for structural studies, footprinting, ligand‑binding analysis and analytical characterization of biomolecules and conjugates.
On-site GMP laboratory services for release, stability and regulatory testing to generate compliant analytical data for conjugates and small-molecule programs.
Custom small-molecule and medicinal chemistry services including route scouting, optimization and supply of intermediates and APIs to support discovery and development.
End-to-end conjugation workflows including selection and execution of conjugation methods, purification and analytical characterization for ADCs, AOCs and other protein conjugates.
Design, custom synthesis and scale-up of payloads and linkers, including integrated payload-linker production for conjugation studies and early CMC supply.
Process optimization and scale-up services to transition synthetic routes and conjugate processes from discovery to pilot and manufacturing scales with CMC support.
Access to high-field NMR instruments and BioNMR experiments for structural studies, footprinting, ligand‑binding analysis and analytical characterization of biomolecules and conjugates.
On-site GMP laboratory services for release, stability and regulatory testing to generate compliant analytical data for conjugates and small-molecule programs.
Custom small-molecule and medicinal chemistry services including route scouting, optimization and supply of intermediates and APIs to support discovery and development.
Expertise Areas
- Antibody-drug conjugate (ADC) development
- Bioconjugation and site-specific conjugation
- Payload and linker chemistry and scale-up
- Structural characterization using high-field NMR
Key Technologies
- High-field NMR spectroscopy and BioNMR experiments
- Multidimensional NMR (2D/3D, multinuclear, HSQC)
- Site-specific conjugation chemistries
- Payload-linker synthetic chemistry
News & Updates
NJ Bio will showcase its latest ADC research and novel characterization tools at the AACR Annual Meeting in April 2024.
NJ Bio introduces its innovative siteDAR© tool for accelerating ADC development through advanced structural analysis.
A comprehensive review on the technological advancements and therapeutic potential of antibody-oligonucleotide conjugates.
NJ Bio was recognized for its excellence in ADC research services and commitment to innovation.
NJ Bio will showcase its latest ADC research and novel characterization tools at the AACR Annual Meeting in April 2024.
NJ Bio introduces its innovative siteDAR© tool for accelerating ADC development through advanced structural analysis.
A comprehensive review on the technological advancements and therapeutic potential of antibody-oligonucleotide conjugates.
NJ Bio was recognized for its excellence in ADC research services and commitment to innovation.